Advanced Enzyme Technologies IPO
Advanced Enzyme Technologies IPO — date, price band, lot size & details 2016
Advanced Enzyme Technologies listed on 1 Aug 2016 at ₹1,210, 35% above the ₹896 issue price.
Advanced Enzyme Technologies researches, makes and markets enzyme based products for healthcare, nutrition and bio processing. Its total income was Rs 294.64 crore in FY2016.
Stock price
Advanced Enzyme Technologies is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 14 November.
- Open 20 Jul 2016
- Close 22 Jul 2016
- Allotment 28 Jul 2016
- Refund/credit TBA
- Listing 01 Aug 2016
Issue summary
The terms of the offer, as filed.
| IPO Dates | 20 to 22 Jul, 2016 |
|---|---|
| Price Band | ₹880 – ₹896 |
| Face Value | ₹10 |
| Lot Size | 16 Shares |
| Issue Size | ₹411.49 Cr |
| Sale Type | Fresh capital cum OFS |
| Listing On | BSE, NSE |
| Employee Discount | Rs 86.00 per share |
| Registrar | MUFG Intime India Private Limited |
| Min Investment | ₹ 14,336 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 16 shares at the ₹896 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 16 | ₹14,336 |
| Retail (max) | 13 | 208 | ₹1,86,368 |
| S-HNI (min) | 14 | 224 | ₹2,00,704 |
| S-HNI (max) | 69 | 1,104 | ₹9,89,184 |
| B-HNI (min) | 70 | 1,120 | ₹10,03,520 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 4
- 01It makes over 400 proprietary products from 60 enzymes.
- 02Profit after tax rose from Rs 21.35 crore in FY2014 to Rs 79.33 crore in FY2016.
- 03EBITDA was Rs 138.23 crore in FY2016, a high margin on income.
- 04Total borrowing fell from Rs 126.61 crore in FY2014 to Rs 68.39 crore in FY2016.
Risks · 5
- 01Total income fell from Rs 240.48 crore in FY2014 to Rs 224.27 crore in FY2015 before recovering.
- 02Rs 361.30 crore of the Rs 411.49 crore issue went to selling shareholders.
- 03Its US subsidiary needed Rs 40.00 crore from the issue to repay loans, which adds overseas risk.
- 04Enzymes are a niche market with strong global rivals; net worth was Rs 278.73 crore.
- 05The promoters and promoter group held about 66.50% after the issue.
Three years of numbers
All figures in ₹ crore, as reported in the Advanced Enzyme Technologies offer document.
| Metric | 31 Mar 2016 | 31 Mar 2015 | 31 Mar 2014 |
|---|---|---|---|
| Assets | 451.65 | 418.09 | 408.28 |
| Total Income | 294.64 | 224.27 | 240.48 |
| Profit After Tax | 79.33 | 50.94 | 21.35 |
| EBITDA | 138.23 | 90.86 | 103.78 |
| NET Worth | 278.73 | 210.03 | 166.37 |
| Reserves and Surplus | 256.96 | 188.27 | 144.60 |
| Total Borrowing | 68.39 | 77.65 | 126.61 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Advanced Enzyme Technologies RHP.
Where the money goes
₹68.15 Cr of the issue is earmarked to named objects.
Advanced Enzyme Technologies IPO Anchor Investors
23 anchor investors across 14 fund houses committed ₹122.85 Cr a day before the issue opened.
Anchor investors bid a day before the issue opens and are locked in after allotment, so a book weighted towards domestic mutual funds is generally read as a stronger signal than one filled by short-horizon funds. Browse every anchor investor scheme or fund house we track.
About the company
It makes over 400 proprietary products developed from 60 enzymes.
It works in two main verticals: healthcare and nutrition for humans and animals, and bio processing.
The IPO was Rs 411.49 crore, with Rs 50.19 crore of fresh issue and Rs 361.30 crore of offer for sale, at Rs 896, the top of the Rs 880 to Rs 896 band. Most of the fresh money was for its US subsidiary to repay loans.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Advanced Enzyme Technologies IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Axis Capital
255 issues handledBest listing: Latent View Analytics (+160.0%). Weakest: Shriram Properties (-23.7%).
ICICI Securities
221 issues handledBest listing: Latent View Analytics (+160.0%). Weakest: Bannari Amman Spinning Mills (-25.2%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Advanced Enzyme Technologies?
The current Grey Market Premium is ₹0.
What is the Advanced Enzyme Technologies IPO price band?
₹880 to ₹896, on a face value of ₹10.
When is the allotment?
The basis of allotment is 28 July 2016, with listing on 1 August 2016.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
